Core Insights - Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer treatment [3] - The company will present at two upcoming investor conferences, highlighting its commitment to engaging with investors [1][2] Company Overview - Candel Therapeutics specializes in off-the-shelf multimodal biological immunotherapies that aim to elicit individualized, systemic anti-tumor immune responses [3] - The company has two clinical stage platforms: one based on genetically modified adenovirus and the other on herpes simplex virus (HSV) gene constructs [3] - The lead product candidate from the adenovirus platform, CAN-2409, has completed successful phase 2a clinical trials in non-small cell lung cancer and borderline resectable pancreatic ductal adenocarcinoma, as well as a pivotal phase 3 trial in localized prostate cancer [3] - The lead product candidate from the HSV platform, CAN-3110, is currently in a phase 1b clinical trial for recurrent high-grade glioma [3] - Candel's enLIGHTEN™ Discovery Platform utilizes human biology and advanced analytics to develop new viral immunotherapies for solid tumors [3]
Candel Therapeutics to Present at Upcoming Investor Conferences